Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CEMINASDAQ:HOTHNASDAQ:OBSVNASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsHOTHHoth Therapeutics$1.28+4.1%$0.99$0.58▼$3.80$16.18M0.553.69 million shs1.06 million shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs406 shsSLRXSalarius Pharmaceuticals$1.20+14.3%$0.79$0.45▼$7.20$2.23M0.41.55 million shs511,733 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%HOTHHoth Therapeutics+4.49%-1.54%+49.88%+25.49%+37.60%OBSVObsEva0.00%0.00%0.00%0.00%0.00%SLRXSalarius Pharmaceuticals+14.29%+14.29%+55.74%+40.01%-50.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEMIChembio DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AHOTHHoth Therapeutics2.7045 of 5 stars3.65.00.00.01.60.00.6OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals0.8355 of 5 stars0.05.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEMIChembio Diagnostics 0.00N/AN/AN/AHOTHHoth Therapeutics 3.25Buy$4.00212.50% UpsideOBSVObsEva 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HOTH, CEMI, OBSV, and SLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95HOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AOBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00SLRXSalarius PharmaceuticalsN/AN/AN/AN/A$0.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/AHOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ASLRXSalarius Pharmaceuticals-$5.58M-$4.82N/A∞N/AN/A-324.13%-174.40%8/8/2025 (Estimated)Latest HOTH, CEMI, OBSV, and SLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SLRXSalarius Pharmaceuticals-$2.40-$1.03+$1.37-$1.03N/AN/A5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEMIChembio DiagnosticsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEMIChembio DiagnosticsN/A1.231.04HOTHHoth TherapeuticsN/A15.0915.08OBSVObsEvaN/A0.610.61SLRXSalarius PharmaceuticalsN/A1.011.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEMIChembio Diagnostics8.65%HOTHHoth Therapeutics7.08%OBSVObsEva17.52%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipCEMIChembio Diagnostics3.30%HOTHHoth Therapeutics6.92%OBSVObsEva14.40%SLRXSalarius Pharmaceuticals1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableSLRXSalarius Pharmaceuticals202.13 million2.10 millionNot OptionableHOTH, CEMI, OBSV, and SLRX HeadlinesRecent News About These CompaniesSalarius Pharmaceuticals (NASDAQ:SLRX) Shares Down 8.7% - Here's WhyJune 24 at 2:23 AM | americanbankingnews.comSalarius Granted Nasdaq Extension To Regain Compliance With Listing StandardsJune 18, 2025 | nasdaq.comSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comSalarius Pharmaceuticals announces Langer to join SABApril 17, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory BoardApril 16, 2025 | globenewswire.comSalarius Pharmaceuticals sees cash runway through later part of 2Q25March 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last yearMarch 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | finanznachrichten.deSalarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | globenewswire.comSalarius resumes trial for MDS and CMML treatmentFebruary 3, 2025 | msn.comSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersFebruary 3, 2025 | globenewswire.comSalarius Pharmaceuticals Inc (SLRX) Stock Trading RecapJanuary 17, 2025 | bovnews.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementJanuary 15, 2025 | finanznachrichten.deSalarius Pharmaceuticals Inc (SLRX) Stock: A Deeper Look at Its True PotentialJanuary 14, 2025 | bovnews.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRXJanuary 14, 2025 | globenewswire.comSalarius, Decoy Therapeutics enter definitive merger agreementJanuary 13, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Announces Merger With Decoy Therapeutics To Advance CancerJanuary 13, 2025 | markets.businessinsider.comHouston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatmentJanuary 13, 2025 | bizjournals.comShareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public ShareholdersJanuary 13, 2025 | businesswire.comGold Down Over 1%; Salarius Pharmaceuticals Shares SurgeJanuary 13, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOTH, CEMI, OBSV, and SLRX Company DescriptionsChembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Hoth Therapeutics NASDAQ:HOTH$1.28 +0.05 (+4.07%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.22 -0.06 (-4.69%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Salarius Pharmaceuticals NASDAQ:SLRX$1.20 +0.15 (+14.29%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.10 -0.10 (-7.92%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
